11/21
08:27 am
ptgx
ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. "Rusty" Williams, M.D., Ph.D. as Chairman of the Board [Yahoo! Finance]
Medium
Report
ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. "Rusty" Williams, M.D., Ph.D. as Chairman of the Board [Yahoo! Finance]
11/19
11:41 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.
11/19
08:20 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
11/19
07:48 am
ptgx
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate [Yahoo! Finance]
Low
Report
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate [Yahoo! Finance]
11/19
07:30 am
ptgx
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Low
Report
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
11/18
04:50 pm
ptgx
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor [Yahoo! Finance]
Medium
Report
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor [Yahoo! Finance]
11/18
04:05 pm
ptgx
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
Medium
Report
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
11/11
10:22 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
11/7
04:05 pm
ptgx
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/5
04:05 pm
ptgx
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
Medium
Report
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
11/4
06:37 pm
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.
Medium
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.
10/29
09:27 am
ptgx
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Low
Report
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
9/26
07:31 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Medium
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
9/24
08:10 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is now covered by analysts at TD Cowen. They set a "buy" rating and a $65.00 price target on the stock.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is now covered by analysts at TD Cowen. They set a "buy" rating and a $65.00 price target on the stock.
9/12
12:14 pm
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at HC Wainwright from $40.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at HC Wainwright from $40.00 to $50.00. They now have a "buy" rating on the stock.
9/10
03:20 pm
ptgx
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says [Yahoo! Finance]
Low
Report
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says [Yahoo! Finance]
9/10
01:23 pm
ptgx
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines [Yahoo! Finance]
Low
Report
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines [Yahoo! Finance]
9/9
08:19 am
ptgx
Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years [Yahoo! Finance]
Medium
Report
Despite shrinking by US$82m in the past week, Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 188% over 5 years [Yahoo! Finance]
9/9
08:01 am
ptgx
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $60.00 price target on the stock.
Medium
Report
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $60.00 price target on the stock.
9/3
07:30 am
ptgx
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Low
Report
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024